These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15585910)

  • 1. A mathematical approach for optimizing dendritic cell-based immunotherapy.
    Bocharov G; Ford NJ; Ludewig B
    Methods Mol Med; 2005; 109():19-34. PubMed ID: 15585910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell immunotherapy.
    Sabado RL; Bhardwaj N
    Ann N Y Acad Sci; 2013 May; 1284():31-45. PubMed ID: 23651191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunodominance analysis through interactions of CD8+ T cells and DCs in lymph nodes.
    Wu YU; Xia L; Zhang M; Zhao X
    Math Biosci; 2010 May; 225(1):53-8. PubMed ID: 20138186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy.
    Hradilova N; Sadilkova L; Palata O; Mysikova D; Mrazkova H; Lischke R; Spisek R; Adkins I
    PLoS One; 2017; 12(2):e0171539. PubMed ID: 28187172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breaking tolerance to tumors with dendritic cell-based immunotherapy.
    Mende I; Engleman EG
    Ann N Y Acad Sci; 2005 Nov; 1058():96-104. PubMed ID: 16394129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential approaches for more successful dendritic cell-based immunotherapy.
    Chiang CL; Balint K; Coukos G; Kandalaft LE
    Expert Opin Biol Ther; 2015 Apr; 15(4):569-82. PubMed ID: 25553913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
    Salem ML
    Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
    Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
    Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined immunotherapy with whole tumor lysate-pulsed interleukin-15-activated dendritic cells and cucurbitacin I promotes strong CD8(+) T-cell responses and cures highly aggressive lymphoma.
    Hira SK; Mondal I; Manna PP
    Cytotherapy; 2015 May; 17(5):647-64. PubMed ID: 25769790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell based personalized immunotherapy based on cancer antigen research.
    Kawakami Y; Fujita T; Kudo C; Sakurai T; Udagawa M; Yaguchi T; Hasegawa G; Hayashi E; Ueda Y; Iwata T; Wang Q; Okada S; Tsukamoto N; Matsuzaki Y; Sumimoto H
    Front Biosci; 2008 Jan; 13():1952-8. PubMed ID: 17981682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.
    Van Nuffel AM; Tuyaerts S; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
    J Immunol Methods; 2012 Mar; 377(1-2):23-36. PubMed ID: 22269772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.
    Santin AD; Bellone S; Ravaggi A; Pecorelli S; Cannon MJ; Parham GP
    Obstet Gynecol; 2000 Sep; 96(3):422-30. PubMed ID: 10960637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.
    Kurokawa T; Oelke M; Mackensen A
    Int J Cancer; 2001 Mar; 91(6):749-56. PubMed ID: 11275975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of hematological malignancies using dendritic cells.
    Van de Velde AL; Berneman ZN; Van Tendeloo VF
    Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal treatment strategy for a tumor model under immune suppression.
    Kim KS; Cho G; Jung IH
    Comput Math Methods Med; 2014; 2014():206287. PubMed ID: 25140193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.